Introduction
Bacteraemias represent a major cause of death in industrialized countries such as Europe and the USA, with large increases in incidence and mortality being seen over the past 20 years [1] . For Escherichia coli, a leading pathogen implicated in these infections [2] , an increase in the prevalence of b-lactam resistance, especially concerning the thirdgeneration cephalosporins (3GCs), has been observed recently, according to the annual report of the European Antimicrobial Resistance Surveillance System (http://www. rivm.nl/earss). Three kinds of b-lactamase are commonly responsible for 3GC resistance: extended-spectrum blactamases (ESBLs), OXA-type penicillinases (or oxacillinases) and AmpC cephalosporinases (chromosomal or plasmidmediated). Among ESBLs, the CTX-M b-lactamases have now become most prevalent [3, 4] .
As 3GCs form part of empirical antimicrobial chemotherapy in severe infections, the prevalence of resistance in E. coli is important to evaluate because of the risk of treatment failure. In 2005, a large, prospective multicentre study, COLIB-AFI (http://www.colibafi.net), was conducted to identify the factors of severity associated with E. coli bacteraemia. The present ancillary study aimed to investigate the prevalence and molecular epidemiology of resistance to 3GCs of the COLIBAFI collection, and to analyse clinical features of patients infected by these resistant strains.
Materials and Methods

Study protocol and bacterial strains
The prospective multicentre study COLIBAFI was conducted in 15 hospitals in different areas in France: Paris (eight hospitals), Angers, Brest, Caen, Dijon, Nantes, Rennes and Tours. All except one were university hospitals. During the year 2005, all cases of E. coli bacteraemia, defined on the basis of the isolation of E. coli from one or more sets of blood culture bottles, were collected by the local bacteriology laboratory. Only patients receiving vasopressors before the bacteraemia or patients already included in the study for a previous episode were not considered for inclusion. Overall, 1099 adults were included. Forty-eight patients were excluded either because the E. coli isolate was not available (n = 18) or because clinical data were lacking (n = 30). Thus, the microbiological study was conducted on 1081 strains, and the clinical study concerned 1051 patients. Bacterial identification was performed with the API20E system (bioMerieux, Marcy l'Etoile, France). Antimicrobial susceptibility was determined by the disk diffusion method on MuellerHinton agar, and interpreted according to the 2005 guidelines of the Antibiogram Committee of the French Society for Microbiology (CA-SFM) (http://www.sfm.asso.fr). The strains were sent to a central laboratory (INSERM U722) with clinical features of the patients and antimicrobial susceptibility data. Clinical characteristics, collected by a tandem of senior investigators (an infectious disease clinician and a bacteriologist) included age, sex, underlying chronic disease, immunosuppression, antibiotherapy received within 2 weeks before the bacteraemia, community-acquired or nosocomial infection, portal of entry and clinical outcome. Bacteraemia episodes were defined as community-acquired if the first positive blood culture was obtained <48 h following hospital admission. The full description of the cohort will be published elsewhere (A. Lefort, X. Panhard, O. Clermont, P. L. Woerther, C. Branger, F. Mentré, B. Fantin, M. Wolff, E. Denamur and the COLIBAFI group; personal communication). Strains with decreased susceptibility to cefotaxime and/or ceftazidime according to the 2005 guidelines of the CA-SFM were selected. Strains with decreased susceptibility to cefoxitin were also considered, as this can be a helpful marker with which to detect AmpC production [5] .
Antimicrobial susceptibility testing of the selected strains All selected strains were tested for ESBL production by the double-disk synergy test [6] . For the strains with a negative test result, MICs of cefoxitin, cefotaxime, ceftazidime and cefepime were determined by the Etest diffusion method (AB Biodisk, Solna, Sweden).
Molecular characterization of b-lactamases
For strains with a positive double-disk synergy test result, characterization of ESBLs was performed by specific PCR amplification and sequencing [7] .
For strains with a negative double-disk synergy test result, the chromosomal ampC gene, its promoter and its attenuator were amplified and sequenced with primers Int-B2 and Int-HN [8] . Mutations were studied by comparison with the published ampC gene sequence of E. coli K-12 (GenBank accession number NC_000913). Plasmid-mediated AmpC cephalosporinase was detected with a multiplex PCR method [9] and identified by sequencing.
The strains were also screened for the presence of an OXA-type b-lactamase by PCR [10] , and this was followed by sequencing to identify the bla OXA gene.
Strain genetic background analysis
Phylogenetic grouping of the E. coli strains was determined by a PCR-based method [11] . The strains were screened for 17 genes encoding putative virulence factors (sfa/foc, iroN, iutA, iha, papC, papG (II and III alleles), hlyC, cnf1, hra, sat, ire, usp, chromosomal ompT, ibeA, fyuA, irp2 and traT) by PCR [12] . For each strain, a virulence score was defined as the sum of virulence factors present over the 17 tested. Twentyfive O-types were determined with a molecular approach based on allele-specific PCR [13] in the 3GC-resistant (3GC-R) strains (see Table S1 for a list of the primers used). They include the O-types most frequently found in extra-intestinal pathogenic [13] and ESBL-producing [14, 15] strains. An allele-specific PCR of the pabB gene was used to detect strains belonging to the O25b:H4-ST131 clone [16] . Pulsedfield gel electrophoresis was performed with a CHEF DRII System (BioRad, Marnes-la-Coquette, France) using genomic DNA digested with XbaI [17] . A dendrogram was constructed using the Dice similarity coefficient, and the UPGMA algorithm was used to cluster the strains. 
Statistical analysis
The 1081 strains were considered for analysis concerning microbiological data. Resistance to other antibiotics, phylogenetic group and virulence factor score were compared between 3GC-R strains (n = 41) and the 3-GC-susceptible (3GC-S) strains (n = 1040). A second comparison was performed between the ESBL-producing strains (n = 19) and the AmpC phenotype-expressing strains (n = 18). The clinical characteristics of 1051 patients were studied with the available data. As above, two comparisons were made.
Comparisons of discrete variables were performed with Fisher's exact test, and comparisons of continuous variables were performed using Wilcoxon-Mann-Whitney tests. All tests were two-sided, with a type I error of 0.05. Risk factors for 3GC resistance were also studied by backward multivariate logistic regression. The statistical analysis was performed using SAS software version 9.1.
Results and Discussion
Overall, 41 of 1081 strains (3.8% (95% CI 2.7-5.1%)) showed decreased susceptibility to at least one of the 3GCs. This rate is close to the percentage of 3% described for bacteraemias in France in 2005 by the surveillance network ONERBA (http://www.onerba.org). Thus, because of the large number of strains included and the participation of several hospitals in different areas, the COLIBAFI study seems to be representative of the situation regarding antimicrobial resistance of E. coli in France.
ESBLs and AmpC, both equally represented, are the main causes of resistance to 3GCs
Strains with an ESBL phenotype. The double-disk synergy test detected 19 ESBL-producing E. coli strains, 18 of which belonged to the CTX-M group and only one to the TEM family (TEM-52) ( Table 1 ). This result shows that the great majority of ESBL-producing E. coli strains responsible for bacteraemia carry a bla CTX-M gene, confirming the observation of the worldwide dissemination of this type of ESBL since the 2000s [3] , both in the hospital environment and in the community [4, 18] , with E. coli as a major host. To date, few observations have been made on the prevalence of this mechanism of resistance in such serious infections. In Spain, two recent studies, conducted between October 2004 and January 2006, concerning community-onset and nosocomial bacteraemia caused by EBSL-producing E. coli, found prevalences of CTX-M enzymes of, respectively, 87% and 81%; the enzymes were predominantly of the CTX-M-14 type [19, 20] . However, they noted the increasing prevalence of the CTX-M-15 type, in relation to the worldwide spread of the ST131 clone. In the COLIBAFI study, two enzymes were predominant: CTX-M-15 (50%) and CTX-M-14 (30%).
Strains with an AmpC phenotype. Eighteen strains had reduced susceptibility to cefoxitin (MIC >32 mg/L) and to at least one of the 3GCs tested, but produced no ESBL or OXA-type penicillinase. This phenotype was compatible with the overproduction of the chromosomal AmpC enzyme resulting from mutations in the ampC gene and/or acquisition of a plasmid-mediated AmpC.
Plasmid-mediated AmpCs, all of the CMY-2 type, were detected in five strains (28%). The predominance of this type of enzyme has been described in Europe [21, 22] and in North America [5, 23] .
The promoter region of the ampC gene of these strains was investigated. In 11 strains, an association of five mutations (in positions )88, )82, )42, )18 and )1) was found ( Table 2 ). The -42 (C fi T) transition is known to increase the strength of the promoter by creating a new perfect consensus sequence, TTTACA, separated by 17 bp from a new -10 sequence created by the -18 (G fi A) transition [24] . Strains lacking this pattern displayed other mutations known to enhance the strength of the promoter: the transversion -32 (T fi A) in the -35 box [24] , or single-nucleotide insertions between the -35 box and the -10 box. Only two strains (08-152 and 10-020) had a promoter region strictly identical to that of E. coli K-12, but they both harboured a plasmid-mediated AmpC. Finally, four strains with an MIC for cefepime ‡4 mg/L had additional mutations in the attenuator region (in position +20 or +23) ( Table 2) , which might increase transcription [25] . All of these findings are consistent with a recent description of the importance of these mutations in the promoter region of the ampC gene [22] .
The extension of the hydrolysis spectrum of AmpC to cefepime has been related to modifications in several specific locations of the protein, and especially the H-9 helix and the H-10 helix [8, [26] [27] [28] . Indeed, in our study, five strains with cefepime MICs >1 mg/L had amino acid substitutions in these regions ( Table 2 ). The S287N substitution might have a greater impact than the S287C substitution on the increase in the catalytic efficiency of AmpC towards 3GCs [8] , and specifically in E. coli strains belonging to phylogroup A [28] , as observed in our study (Tables 1 and 2 ). The L293P substitution found in strain 08-121 (cefepime MIC of 16 mg/L) has never been described to date in a clinical isolate of E. coli. However, it has already been found in an in vitro mutant of the Enterobacter cloacae P99 reference strain (cefepime MIC of 8 mg/L) [26] and in a clinical isolate of Enterobacter aerogenes (cefepime MIC of 32 mg/L) selected during cefepime treatment [29] .
Strains with an OXA phenotype. Four strains with decreased susceptibility to cefoxitin and showing selective hydrolysis of cefepime produced an OXA-type penicillinase encoded by a bla OXA-1 gene (Table 1 ). This gene was also found in strains producing a CTX-M enzyme. Indeed, the bla OXA-1 gene can be found alone or with the bla CTX-M-15 gene on the same plasmid [3, 30, 31] .
3GC-R strains constitute a diverse population that is more co-resistant and has fewer virulence factors than 3GC-S strains Pulsed-field gel electrophoresis revealed that the 3GC-R strains constitute a diverse population. Six CTX-M-producing strains, of phylogroup B2, were found in a cluster distant from the others (Fig. 1) , and belonged to the recently described widespread intercontinental clone O25b:H4-ST131 [14, 16, 32] . This clone usually includes strains harbouring the bla CTX-M15 gene, but recent studies have shown that other types of ESBL can be found [16, 31] .
The 3GC-R strains had heterogeneous co-resistance profile (Tables 1 and 3 ). They were significantly more resistant than 3GC-S strains to several major antibiotics: ciprofloxacin (p <0.0001), gentamicin (p <0.0001), amikacin (p 0.01), and co-trimoxazole (p <0.0001). Ciprofloxacin resistance was found in 28 of 41 strains, with a significant predominance in the ESBL group vs. the AmpC group (p 0.04). Gentamicin resistance was found in ten of 41 strains: six were CTX-M-15 producers. Co-trimoxazole was inactive in 75.6% of the cases with no difference between ESBL-and AmpC-producing strains. All of these findings concerning multiresistance in ESBLproducing E. coli strains highlight the difficulty in finding an appropriate antimicrobial therapy to cure these severe infections [33] . Phylogroup A was the most common (61%) among the 3GC-R strains, and less common among the 3GC-S strains (p <0.0001), where phylogroups B2 or D are predominant (Table 3) . This result agrees with several observations showing that resistant strains of E. coli belong to phylogroups that are usually considered to have low virulence [7, 34] , i.e. A, B1 and D [35] . Indeed, 3GC-R strains carried significantly fewer virulence factors than 3GC-S strains (p <0.0001). These results also confirm that the trade-off between resistance to fluoroquinolones and virulence [7, 36] is also found in E. coli strains isolated from bacteraemias. Finally, with the exception of the strains belonging to the ST131 clone, only six strains were O-typed ( Table 1 ), indicating that the 3GC-R strains of COLIBAFI do not express the O-types usually described in E. coli strains involved in extra-intestinal infections [13] .
Prior use of antibiotics and underlying chronic disease \are risk factors for development of 3GC-resistant E. coli bacteraemia The majority of the patients developed a communityacquired infection. Several factors were found to be different between the 3GC-S and the 3GCR groups ( Bacteraemias with 3GC-R isolates were more frequently associated with death than bacteraemias with 3GC-S isolates (p 0.0024) ( Table 4 ). The full study of risk factors associated with death in the COLIBAFI study will be presented elsewhere (A. Lefort, X. Panhard, O. Clermont, P. L. Woerther, C. Branger, F. Mentré, B. Fantin, M. Wolff, E. Denamur and the COLIBAFI group; personal communication).
Within the 3GC-R group, male sex was predominant in the ESBL group, which is consistent with previous published data [33] . Immunosuppression (p 0.036) and prior antibiotic treatment (p 0.0041) seemed to be more important risk factors for developing an infection with ESBL-producing E. coli than for developing an infection with an AmpC-overproducing strains. Bacteraemia was no more lethal in the ESBL group than in the AmpC group (Table 4) .
In conclusion the COLIBAFI study showed that, in France in 2005, 3.8% of E. coli strains responsible for bacteraemia had decreased susceptibility to 3GCs. This study relied on a prospective and multicentre approach, making it well representative of French epidemiology. Moreover, the statistical comparison between the 3GC-R group and the 3GC-S group seems to be the best study design with which to investigate factors associated with antimicrobial resistance [20] . However, the low number of 3GC-R strains may have led to an underestimation of the presence of confounding bias. ESBL-producing strains and AmpC producers were equally represented. Resistance was plasmid-mediated in 68.3% of the cases, representing a potentially epidemic Data are no. and percentages of patients, unless otherwise indicated. 3GC-S, susceptible to third-generation cephalosporins (3GCs); 3GC-R, resistant to 3GCs; ESBL, extended-spectrum b-lactamase; p 1 , p-value for the comparison between the 3GC-S group and the 3GC-R group; p 2 , p-value for the comparison between ESBL-producing and AmpC-producing strains; SD, standard deviation.
threat. These 3GC-R strains, mostly community-acquired, were significantly more frequent in patients with underlying chronic disease and were associated with a more severe outcome. Prior use of antibiotics and immunosuppression are greater risk factors for infection by ESBL-producing strains than for infection by AmpC overproducers. Adequate antimicrobial therapy of ESBL-producing strains relies on carbapenems, whereas cefepime could usually be used to treat infections with AmpC producers. The recent revision of the MIC breakpoints for cephalosporins by the European Committee on Antimicrobial Susceptibility Testing (EUCAST: http://www.escmid.org) and the CA-SFM will have an impact on the susceptibility categorization of cefepime. The initial breakpoint was lowered from 4 mg/L to 1 mg/L, which might decrease the number of strains categorized as susceptible among the AmpC-producing strains. This could lead to an increase in the use of carbapenems, with the threat of contributing to the emergence and spread of carbapenemresistant E. coli [37] .
